Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.79 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.68 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.66 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | HTR2B | P41595 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.66 |
| ▸ | MPO | P05164 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | NQO2 | P16083 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL674415 | 0.88 | KDM4E (1.00) | KDM4EGPR84MTNR1AMTNR1BKMT2A | |
| SCHEMBL2686551 | 0.87 | KDM4E (0.77) | KDM4EGPR84MTNR1AMTNR1BKMT2A | |
| SCHEMBL1461935 | 0.87 | KDM4E (0.77) | KDM4EGPR84MTNR1AMTNR1BKMT2A | |
| SCHEMBL6945002 | 0.87 | KDM4E (0.77) | KDM4EGPR84MTNR1AMTNR1BKMT2A | |
| SCHEMBL1395687 | 0.87 | KDM4E (0.77) | KDM4EGPR84MTNR1AMTNR1BKMT2A | |
| SCHEMBL14665122 | 0.86 | KDM4E (0.75) | KDM4EGPR84MTNR1AMTNR1BKMT2A | |
| SCHEMBL2625194 | 0.86 | KDM4E (0.75) | KDM4EGPR84MTNR1AMTNR1BKMT2A | |
| Hydrochloric Acid SCHEMBL5013119 | 0.86 | KDM4E (0.75) | KDM4EGPR84MTNR1AMTNR1BKMT2A | |
| SCHEMBL4889276 | 0.86 | MTNR1A (0.70) | KDM4EGPR84MTNR1AMTNR1BKMT2A | |
| SCHEMBL11746973 | 0.86 | KDM4E (0.80) | KDM4EGPR84MTNR1AMTNR1BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20210348139-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-11-11 | — | — | US | disclosed |
| US-20200123512-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-04-23 | — | — | US | disclosed |
| US-10544402-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS INC. (US) | 2020-01-28 | — | — | US | disclosed |
| EP-2828385-B1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | CODEXIS INC (US) | 2018-02-07 | — | — | EP | disclosed |
| US-20170283781-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-10-05 | — | — | US | disclosed |
| US-20170283781-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-10-05 | — | — | US | disclosed |
| US-9708588-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708588-B2 | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs | CODEXIS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160289649-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-10-06 | — | — | US | disclosed |
| US-20150072383-A1 | BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-03-12 | — | — | US | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| EP-2260835-A2 | Composition for proteasome inhibition | Proteolix, Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261236-A2 | Composition for proteasome inhibition | Proteolix, Inc. (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2006063154-A1 | COMPOSITION FOR PROTEASOME INHIBITION | PROTEOLIX, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2005111008-A2 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | KDM4E 3330/4885GPR84 4041/4885MTNR1A 4258/4885 |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | KDM4E 2512/4885GPR84 4585/4885MTNR1A 2726/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | KDM4E 3330/4885GPR84 4041/4885MTNR1A 4258/4885 |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | KDM4E 3184/4885GPR84 1604/4885MTNR1A 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.